Lead Biostatistician
Thermo Fisher Scientific- Full Time
- Junior (1 to 2 years)
Iambic is seeking a Principal Statistical Programmer to join its Clinical Development team. This role is crucial for supporting statistical programming activities across all phases of clinical trials, from Phase I to regulatory submission. The ideal candidate will be a hands-on leader with extensive SAS programming expertise, a deep understanding of CDISC standards, regulatory requirements, and clinical trial processes. This position will also involve collaboration with data science and machine learning groups to integrate clinical data with existing AI infrastructure.
Required:
Preferred:
Founded in 2020 and headquartered in San Diego, California, Iambic Therapeutics is leveraging a unique AI-driven drug-discovery platform to transform the therapeutics landscape. The company has assembled a world-class team of AI experts and experienced drug hunters with proven track records in developing clinically validated therapeutics. Iambic's platform is designed to deliver high-quality, differentiated therapeutics to the clinical stage rapidly and across various target classes and mechanisms of action. The company is advancing an internal pipeline of clinical assets to address critical unmet patient needs. Learn more at iambic.ai.
Iambic's mission is to deliver better medicines through innovations in AI-based discovery technologies. The company fosters a culture that is significantly strengthened by the diversity of its people, including differences in background, culture, national origin, religion, sexual orientation, and life experiences. Iambic is committed to building an inclusive environment where a diverse group of talented individuals collaborate to discover therapeutics and create technologies.
Iambic offers industry-leading competitive pay, company-paid healthcare, flexible spending accounts, voluntary life insurance, 401K matching, and uncapped vacation time.
Develops therapies for CNS disorders
Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.